



Work Group Interpretation of Pfizer's MenABCWY Vaccine Clinical Trials Data

Sam Crowe, PhD, MPH
Meningococcal Vaccines Work Group Lead

February 23, 2023

Policy Questions for Each Pentavalent Vaccine

- Should the pentavalent vaccine be included as an option for MenACWY/MenB vaccination in people currently recommended to receive both vaccines?
 - For example, 16 year olds¹
- Should the pentavalent vaccine be included as an option for people currently recommended to receive MenACWY only?
 - For example, 11–12 year olds
- Should the pentavalent vaccine be included as an option for people currently recommended to receive MenB only?
 - For example, during a serogroup B outbreak

¹ 16 year olds who decide to receive the MenB vaccine based on shared clinical decision-making

Pfizer MenABCWY Vaccine and Trials Overview

- Comprised of Nimenrix (serogroups ACWY) and Trumenba (serogroup B)
 - Trumenba currently licensed and available in US, 10y through 25y
 - Nimenrix not licensed in US but used extensively elsewhere, 6w and older
- Two clinical trials completed (NCT03135834, NCT04440163)
 - Assessed safety and immunogenicity of pentavalent vaccine
 - Compared to Trumenba (MenB) and Menveo (MenACWY)
 - Included participants 10 through 25 years of age
 - Studied single and two dose (0, 6m) schedules
 - 4-year persistence and booster dose were evaluated
- Extended interval study underway (NCT04440176)
 - Study arm 1 — 0, 12m (data available)
 - Study arm 2 — 0, 36m

Safety

- Assessed by monitoring for and comparing local reactions, systemic events, medically attended adverse events, serious adverse events, and newly diagnosed chronic medical conditions
- Local reactions within 7 days after vaccination
 - Includes pain, redness, swelling
 - Comparison between pentavalent and MenB vaccine only
 - Slightly higher percentage of participants had a local reaction to pentavalent vaccine for both 1st and 2nd doses
- Systemic events within 7 days after vaccination
 - Includes fatigue, headache, muscle pain, joint pain, chills, diarrhea, vomiting, fever
 - Similar percentage of participants experienced systemic events in pentavalent vaccine group and in MenACWY+MenB group
 - Percentage varied slightly between groups by systemic event and by dose

Safety, Continued

- Medically attended adverse events
 - Similar percentages between study groups (both <15%)
- Serious adverse events
 - More reported for pentavalent group (0.4% vs. 0%)
 - None assessed to be related to pentavalent vaccine (e.g., hospitalization due to other medical conditions)
- Newly diagnosed chronic medical conditions (NDCMC)
 - More reported for pentavalent group (1.1% vs. 0.3%)
 - Higher number of participants with attention-deficit/hyperactivity disorder (ADHD) in pentavalent group – most with related symptoms before entering study
- Higher risk patients (e.g., complement deficiency) not included in trials

Immunogenicity Standards


- Serogroups A, C, W, and Y
 - Percentage of participants achieving MenACWY seroresponse in hSBA titer 1 month after 1 dose and 1 month after 2 doses
 - Seroresponse is defined as a 4-fold increase in titer over baseline
- Serogroup B
 - Percentage of participants achieving MenB seroresponse in hSBA 1 month after 2 doses
 - Composite response provided
 - Seroresponse is defined as a 4-fold increase in titer over baseline

Immunogenicity for Serogroups A, C, W, Y

- 1 dose of the pentavalent vaccine is noninferior to 1 dose of MenACWY in both ACWY-naïve and ACWY-primed participants 1 month after administration


ACWY-Naïve

Percentage of participants achieving hSBA seroresponse* 1 month after vaccination for serogroups ACWY



ACWY-Primed

Percentage of participants achieving hSBA seroresponse* 1 month after vaccination for serogroups ACWY




Immunogenicity for Serogroups A, C, W, Y

- 2 doses of the pentavalent vaccine given 6 months apart are noninferior to 1 dose of MenACWY in both naïve and primed participants 1 month after administration


ACWY-Naïve

Percentage of participants achieving hSBA seroresponse* 1 month after vaccination for serogroups ACWY




ACWY-Primed

Percentage of participants achieving hSBA seroresponse* 1 month after vaccination




Seroprotection for ACWY-Naïve Participants after 4 Years

- Seroprotection persists up to 4 years in naïve participants after a 2-dose series




Seroprotection for ACWY-Primed Participants after 4 Years

- Seroprotection persists up to 4 years in primed participants after a 2-dose series




Immunogenicity for Serogroup B

- 2 doses of the pentavalent vaccine given 6 months apart are noninferior to 2 doses of MenB in naïve participants (primed not assessed)



Seroprotection for Serogroup B-Naïve Participants

- Waning of immunity for the pentavalent vaccine is very similar to that observed with MenB, dropping substantially by 12 months post-dose 2



Additional Work Group Reflections

- Data not presented on 3-dose schedule of pentavalent vaccine
 - 3-dose schedule of Trumenba currently recommended for certain high-risk groups (e.g., people affected by a serogroup B outbreak)
- Data not available in people older than 25 years
 - MenB vaccines licensed for 10–25 years
 - MenACWY vaccines licensed up to 55 years or older depending on vaccine

Final Reflections and Next Steps

- Pfizer's MenABCWY vaccine appears to be noninferior to MenACWY+MenB based on clinical trial data presented
- Data gaps
 - 3-dose schedule for high-risk populations
 - Adults older than 25 years
- Next steps
 - Reviewing additional immunologic persistence data for a single dose
 - GRADE and EtR — will focus on pentavalent vaccine studies
 - Cost effectiveness study will be conducted

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

